Michelle Brennan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michelle Brennan has a total of 168 co-authors. Here are the top co-authors by number of shared publications:
- Richard J. DiPaolo
Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, Saint Louis, Missouri, USA
31 shared publications - Ryan M. Teague
Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, St. Louis, Missouri
18 shared publications - Elise Alspach
Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, St. Louis, Missouri
17 shared publications - Katey S. Hunt
Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, St. Louis, Missouri
17 shared publications - David DeBruin
Department of Biochemistry and Molecular Biology, Saint Louis University School of Medicine, St. Louis, Missouri, USA
16 shared publications - Stephen T. Ferris
Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA
16 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Momordicine-I Suppresses Head and Neck Cancer Growth by Reprogrammimg Immunosuppressive Effect of the Tumor-Infiltrating Macrophages and B Lymphocytes
Supplementary Figure 4: A, Volcano plot illustrates the expression of genes in cDC2 populations in the treated group as compared to the control tumors. The x-axis represents log2 -fold change, and the y-axis denotes (−log10) p-value showing statistical significance. The horizontal dashed line is p =0.05 [−log10(0.05) = 1.3], the cut-off threshold. B, Violin plot showing Chil3, Prnp, Slfn4, and Cxcl3 expression in control vs. M-I-treated tumors.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Momordicine-I Suppresses Head and Neck Cancer Growth by Reprogrammimg Immunosuppressive Effect of the Tumor-Infiltrating Macrophages and B Lymphocytes
Supplementary Figure 4: A, Volcano plot illustrates the expression of genes in cDC2 populations in the treated group as compared to the control tumors. The x-axis represents log2 -fold change, and the y-axis denotes (−log10) p-value showing statistical significance. The horizontal dashed line is p =0.05 [−log10(0.05) = 1.3], the cut-off threshold. B, Violin plot showing Chil3, Prnp, Slfn4, and Cxcl3 expression in control vs. M-I-treated tumors.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 3 from T-Cell Expression of CXCL13 is Associated with Immunotherapy Response in a Sex-Dependent Manner in Patients with Lung Cancer
Supplemental Figure 3: Characterization of CD4+ and CD8+ T cell populations infiltrating tumors from male and female patients with NSCLC from Liu et al.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 3 from T-Cell Expression of CXCL13 is Associated with Immunotherapy Response in a Sex-Dependent Manner in Patients with Lung Cancer
Supplemental Figure 3: Characterization of CD4+ and CD8+ T cell populations infiltrating tumors from male and female patients with NSCLC from Liu et al.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Momordicine-I Suppresses Head and Neck Cancer Growth by Reprogrammimg Immunosuppressive Effect of the Tumor-Infiltrating Macrophages and B Lymphocytes
Supplementary Figure 3: A, Violin plots showing the number of genes (top panel) and unique molecular identifier (UMI) (bottom panel) of control and M-I-treated CD45+ cells. B, Number of the genes in each cluster is shown.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Momordicine-I Suppresses Head and Neck Cancer Growth by Reprogrammimg Immunosuppressive Effect of the Tumor-Infiltrating Macrophages and B Lymphocytes
Supplementary Figure 3: A, Violin plots showing the number of genes (top panel) and unique molecular identifier (UMI) (bottom panel) of control and M-I-treated CD45+ cells. B, Number of the genes in each cluster is shown.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Momordicine-I Suppresses Head and Neck Cancer Growth by Reprogrammimg Immunosuppressive Effect of the Tumor-Infiltrating Macrophages and B Lymphocytes
Supplementary Figure 1: MOC2 cells treated with bitter melon extract (BME) or momordicine -I (M-I). Cell number was enumerated by the Trypan blue dye exclusion method after 48 hours of treatment. The results shown are the average of three independent experiments. The small bar indicates the standard error.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Momordicine-I Suppresses Head and Neck Cancer Growth by Reprogrammimg Immunosuppressive Effect of the Tumor-Infiltrating Macrophages and B Lymphocytes
Supplementary Figure 1: MOC2 cells treated with bitter melon extract (BME) or momordicine -I (M-I). Cell number was enumerated by the Trypan blue dye exclusion method after 48 hours of treatment. The results shown are the average of three independent experiments. The small bar indicates the standard error.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 4 from T-Cell Expression of CXCL13 is Associated with Immunotherapy Response in a Sex-Dependent Manner in Patients with Lung Cancer
Supplemental Figure 4: TCR repertoire analysis reveals sex-based differences in the association between T cell clonal expansion and expression of CXCL13.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 4 from T-Cell Expression of CXCL13 is Associated with Immunotherapy Response in a Sex-Dependent Manner in Patients with Lung Cancer
Supplemental Figure 4: TCR repertoire analysis reveals sex-based differences in the association between T cell clonal expansion and expression of CXCL13.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from T-Cell Expression of CXCL13 is Associated with Immunotherapy Response in a Sex-Dependent Manner in Patients with Lung Cancer
Supplemental Figure 2: Sex-based differences in CXCL13 expression level and frequency of CXCL13+ T cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from T-Cell Expression of CXCL13 is Associated with Immunotherapy Response in a Sex-Dependent Manner in Patients with Lung Cancer
Supplemental Figure 2: Sex-based differences in CXCL13 expression level and frequency of CXCL13+ T cells.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from T-Cell Expression of CXCL13 is Associated with Immunotherapy Response in a Sex-Dependent Manner in Patients with Lung Cancer
Supplemental Figure 1: Characterization of CD4+ and CD8+ T cell populations infiltrating tumors from male and female patients with NSCLC.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from T-Cell Expression of CXCL13 is Associated with Immunotherapy Response in a Sex-Dependent Manner in Patients with Lung Cancer
Supplemental Figure 1: Characterization of CD4+ and CD8+ T cell populations infiltrating tumors from male and female patients with NSCLC.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Momordicine-I Suppresses Head and Neck Cancer Growth by Reprogrammimg Immunosuppressive Effect of the Tumor-Infiltrating Macrophages and B Lymphocytes
Supplementary Figure 2: Image showing the gating strategy of flow cytometry and cell sorting.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Momordicine-I Suppresses Head and Neck Cancer Growth by Reprogrammimg Immunosuppressive Effect of the Tumor-Infiltrating Macrophages and B Lymphocytes
Supplementary Figure 2: Image showing the gating strategy of flow cytometry and cell sorting.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from T-Cell Expression of CXCL13 is Associated with Immunotherapy Response in a Sex-Dependent Manner in Patients with Lung Cancer
Emerging evidence in preclinical models demonstrates that antitumor immunity is not equivalent between males and females. However, more investigation in patients and across a wider range of cancer types is needed to fully understand sex as a variable in tumor immune responses. We investigated differences in T-cell responses between male and female patients with lung cancer by performing sex-based analysis of single cell transcriptomic datasets. We found that the transcript encoding CXC motif chemokine ligand 13 (CXCL13), which has recently been shown to correlate with T-cell tumor specificity, is expressed at greater levels in T cells isolated from female compared with male patients. Furthermore, increased CXCL13 expression was associated with response to PD1–targeting immunotherapy in female but not male patients. These findings suggest that there are sex-based differences in T-cell function required for response to anti–PD1 therapy in lung cancer that may need to be considered during patient treatment decisions.See related Spotlight by Cruz-Hinojoza and Stromnes, p. 952
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from T-Cell Expression of CXCL13 is Associated with Immunotherapy Response in a Sex-Dependent Manner in Patients with Lung Cancer
Emerging evidence in preclinical models demonstrates that antitumor immunity is not equivalent between males and females. However, more investigation in patients and across a wider range of cancer types is needed to fully understand sex as a variable in tumor immune responses. We investigated differences in T-cell responses between male and female patients with lung cancer by performing sex-based analysis of single cell transcriptomic datasets. We found that the transcript encoding CXC motif chemokine ligand 13 (CXCL13), which has recently been shown to correlate with T-cell tumor specificity, is expressed at greater levels in T cells isolated from female compared with male patients. Furthermore, increased CXCL13 expression was associated with response to PD1–targeting immunotherapy in female but not male patients. These findings suggest that there are sex-based differences in T-cell function required for response to anti–PD1 therapy in lung cancer that may need to be considered during patient treatment decisions.See related Spotlight by Cruz-Hinojoza and Stromnes, p. 952
- 26 May 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- p. OF1-OF12
Reduced Tumor Control in Males Can Result from Impaired CD4+ T-cell Help through the CD40L–CD40 Pathway
Sex-based differences in cancer incidence are incompletely understood, but potential roles for the immune system are beginning to emerge. CD4+ T cells play a central role in coordinating antitumor immunity. In addition to cytokine production, CD40L expression on CD4+ T cells provides necessary helper signaling to dendritic cells (DC) that is required for the priming of cytotoxic tumor-specific CD8+ T cells. Despite these critical functions, the impact of biological sex on the CD4+ T-cell response to cancer remains unknown. In this study, we demonstrate that impaired immune-mediated tumor control in male mice compared with female mice is driven by disparate CD4+ T-cell responses in a mouse model of bladder cancer. We found that CD40L expression was reduced on CD4+ T cells isolated from males via a mechanism predominantly driven by cell-intrinsic androgen receptor signaling, resulting in decreased DC licensing through CD40 within tumor-draining lymph nodes. These deficits resulted in decreased helper CD4+ T-cell frequencies and impaired CD8+ T-cell function within the male tumor microenvironment, which could be rescued by targeting the CD40L–CD40 axis. Our findings identify a novel mechanism of CD4+ T cell–based sex differences in the immune response to cancer that impairs tumor control.
- 26 May 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- p. OF1-OF12
Reduced Tumor Control in Males Can Result from Impaired CD4+ T-cell Help through the CD40L–CD40 Pathway
Sex-based differences in cancer incidence are incompletely understood, but potential roles for the immune system are beginning to emerge. CD4+ T cells play a central role in coordinating antitumor immunity. In addition to cytokine production, CD40L expression on CD4+ T cells provides necessary helper signaling to dendritic cells (DC) that is required for the priming of cytotoxic tumor-specific CD8+ T cells. Despite these critical functions, the impact of biological sex on the CD4+ T-cell response to cancer remains unknown. In this study, we demonstrate that impaired immune-mediated tumor control in male mice compared with female mice is driven by disparate CD4+ T-cell responses in a mouse model of bladder cancer. We found that CD40L expression was reduced on CD4+ T cells isolated from males via a mechanism predominantly driven by cell-intrinsic androgen receptor signaling, resulting in decreased DC licensing through CD40 within tumor-draining lymph nodes. These deficits resulted in decreased helper CD4+ T-cell frequencies and impaired CD8+ T-cell function within the male tumor microenvironment, which could be rescued by targeting the CD40L–CD40 axis. Our findings identify a novel mechanism of CD4+ T cell–based sex differences in the immune response to cancer that impairs tumor control.